Payment overview · 2025
General Payments
$235.92
13 reported records · 5 companies
Healthcare provider profile · identity verified
Brian J Peerless, MD
Allopathic & Osteopathic Physicians|Family Medicine · BLUE ASH, OH · NPI 1962484758
Verified facts
What the public records show
CMS Open Payments records show Brian J Peerless, MD received $235.92 in general payments during 2025 across 13 reported records.
Exact Sciences Corporation accounted for 59.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $141.11 | 59.8% | 8 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.79 | 12.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.95 | 10.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.62 | 9.6% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $18.45 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $235.92 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $141.11 | 8 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.79 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 663 | 180 |
| Lisinopril | Lisinopril | 247 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 245 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 198 | 52 |
| Metformin Hcl | Metformin Hcl | 173 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 171 | 46 |
| Losartan Potassium | Losartan Potassium | 170 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 36 |
| Furosemide | Furosemide | 129 | 35 |
| Bupropion Xl | Bupropion Hcl | 128 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 37 |
| Jardiance | Empagliflozin | 124 | 28 |
| Meloxicam | Meloxicam | 124 | 33 |
| Gabapentin | Gabapentin | 121 | 32 |
| Eliquis | Apixaban | 120 | 24 |
| Omeprazole | Omeprazole | 120 | 43 |
| Trazodone Hcl | Trazodone Hcl | 112 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 23 |
| Mounjaro | Tirzepatide | 105 | 17 |
| Simvastatin | Simvastatin | 98 | 26 |
| Alprazolam | Alprazolam | 94 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 17 |
| Metformin Hcl Er | Metformin Hcl | 80 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 19 |
| Synthroid | Levothyroxine Sodium | 71 | 13 |
| Sertraline Hcl | Sertraline Hcl | 68 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 27 |
| Ezetimibe | Ezetimibe | 61 | 20 |
| Lorazepam | Lorazepam | 58 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | 13 |
| Trulicity | Dulaglutide | 55 | suppressed |
| Allopurinol | Allopurinol | 53 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 21 |
| Montelukast Sodium | Montelukast Sodium | 45 | suppressed |
| Clonazepam | Clonazepam | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Carvedilol | Carvedilol | 38 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 11 |
| Tramadol Hcl | Tramadol Hcl | 37 | 13 |
| Famotidine | Famotidine | 36 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 26 |
| Temazepam | Temazepam | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 22 |
| Azithromycin | Azithromycin | 24 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 12 |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 18 |
| Pregabalin | Pregabalin | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Glipizide | Glipizide | 20 | suppressed |
| Prednisone | Prednisone | 20 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Diazepam | Diazepam | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Repatha Syringe | Evolocumab | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | 11 |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $235.92 · 13 records | Exact Sciences Corporation | Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Kerendia, REXULTI | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error